BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

HealthHORIZON-RIAID: 101057442
EC Contribution
โ‚ฌ225,615
Consortium Size
29 orgs
Start Year
2022
โ–ถSummary

REMEDi4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDi4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDi4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases.The REMEDi4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach. Working closely together with research funders and the patient community, REMEDi4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDi4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into the market, through its complete value chain and consensus-based policy development mission.

Consortium (29)

๐Ÿ‡ณ๐Ÿ‡ฑ EATRIS ERICNL
coordinator
๐Ÿ‡ง๐Ÿ‡ช ANTIKANKERFONDS - FONDS ANTICANCER-ANTICANCER FUNDBE
partner
๐Ÿ‡ฌ๐Ÿ‡ง BEACON: FOR RARE DISEASES LTDGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTEDE
partner
๐Ÿ‡ช๐Ÿ‡ธ CHEMOTARGETS SLES
partner
๐Ÿ‡ฎ๐Ÿ‡น DOMPE FARMACEUTICI SPAIT
partner
๐Ÿ‡ซ๐Ÿ‡ท ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORKFR
partner
๐Ÿ‡ซ๐Ÿ‡ท EURORDIS - RARE DISEASES EUROPEFR
partner
๐Ÿ‡ฉ๐Ÿ‡ช FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EVDE
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBREES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJALES
partner
๐Ÿ‡ซ๐Ÿ‡ฎ HELSINGIN YLIOPISTOFI
partner
๐Ÿ‡ฎ๐Ÿ‡น ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRIIT
partner
๐Ÿ‡ฎ๐Ÿ‡น ISTITUTO NAZIONALE TUMORI Fondazione PascaleIT
partner
๐Ÿ‡ฎ๐Ÿ‡น ISTITUTO ORTOPEDICO RIZZOLIIT
partner
๐Ÿ‡ธ๐Ÿ‡ช KAROLINSKA INSTITUTETSE
partner
๐Ÿ‡ฌ๐Ÿ‡ง LIFEARCGB
partner
๐Ÿ‡ง๐Ÿ‡ช MEDICINES FOR EUROPEBE
partner
๐Ÿ‡ช๐Ÿ‡ธ SERVICIO MADRILENO DE SALUDES
partner
๐Ÿ‡ญ๐Ÿ‡บ SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAGHU
partner
๐Ÿ‡ช๐Ÿ‡ธ TEAMIT INSTITUTE S LES
partner
๐Ÿ‡ช๐Ÿ‡ธ TEAMIT RESEARCH SLES
partner
๐Ÿ‡ฌ๐Ÿ‡ง THE UNIVERSITY OF SHEFFIELDGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTSDE
partner
๐Ÿ‡ฌ๐Ÿ‡ง UNIVERSITY COLLEGE LONDONGB
partner
๐Ÿ‡ฌ๐Ÿ‡ง UNIVERSITY OF HULLGB
partner
๐Ÿ‡ธ๐Ÿ‡ฎ UNIVERZA V LJUBLJANISI
partner
๐Ÿ‡ธ๐Ÿ‡ช UPPSALA UNIVERSITETSE
partner
๐Ÿ‡ณ๐Ÿ‡ฑ ZORGONDERZOEK NEDERLAND ZONNL
partner